These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9010862)

  • 41. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
    Cappozzo C
    Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors.
    Wilson BJ; Gardner AE
    Oncol Nurs Forum; 2007 Mar; 34(2):347-53. PubMed ID: 17573299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Managing hematologic toxicities.
    Capo G; Waltzman R
    J Support Oncol; 2004; 2(1):65-79. PubMed ID: 15330374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary toxicities of cancer therapy.
    Chernecky C; Sarna L
    Crit Care Nurs Clin North Am; 2000 Sep; 12(3):281-95. PubMed ID: 11855233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
    Gill P; Litzow M; Buckner J; Arndt C; Moynihan T; Christianson T; Ansell S; Galanis E
    Cancer; 2008 Apr; 112(8):1805-11. PubMed ID: 18300237
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nursing guidelines and discharge planning for patients receiving recombinant interleukin-2.
    Caliendo G; Joyce D; Altmiller MC
    Semin Oncol Nurs; 1993 Aug; 9(3 Suppl 1):25-31. PubMed ID: 8210791
    [No Abstract]   [Full Text] [Related]  

  • 48. Chemotherapy toxicity assessment using a self-report tool.
    Brinkman P; Hay D; Laubinger P
    Oncol Nurs Forum; 1994; 21(10):1731-3. PubMed ID: 7854935
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Neurotoxicity in chemotherapy].
    Kopp K; Hansen SW
    Sygeplejersken; 1991 Dec; 91(49):4-8. PubMed ID: 1667557
    [No Abstract]   [Full Text] [Related]  

  • 50. [Drug side effects in antineoplastic and immunosuppressive cytostatic therapy].
    Hambsch K; Fischer H
    Z Gesamte Inn Med; 1984 Jan; 39(1):7-14. PubMed ID: 6711064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Late toxic effects of cytotoxic drugs.
    Fortuny IE; Theologides A
    Minn Med; 1974 Jan; 57(1):19-21 passim. PubMed ID: 4592758
    [No Abstract]   [Full Text] [Related]  

  • 52. Dose limiting extramedullary toxicity of high dose chemotherapy.
    Glode LM
    Exp Hematol; 1979; 7 Suppl 5():265-78. PubMed ID: 263244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cutaneous toxicities of cancer therapy.
    Alley E; Green R; Schuchter L
    Curr Opin Oncol; 2002 Mar; 14(2):212-6. PubMed ID: 11880713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prevention and treatment of neurological toxicity. Nursing aspects].
    Peri A; Catalano V; Di Luca L
    Suppl Tumori; 2004; 3(4):S113-4. PubMed ID: 15206233
    [No Abstract]   [Full Text] [Related]  

  • 55. Management of cutaneous symptoms.
    Gallagher J
    Semin Oncol Nurs; 1995 Nov; 11(4):239-47. PubMed ID: 8578031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reducing chemotherapy-associated toxicity in elderly cancer patients.
    Zagonel V; Fratino L; Sacco C; Babare R; Spazzapan S; Gattei V; Improta S; Pinto A
    Cancer Treat Rev; 1996 May; 22(3):223-44. PubMed ID: 8841391
    [No Abstract]   [Full Text] [Related]  

  • 57. Dose-related cutaneous toxicities with etoposide.
    Murphy CP; Harden EA; Herzig RH
    Cancer; 1993 May; 71(10):3153-5. PubMed ID: 8490845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Reduction and withdrawal of chemotherapy].
    Yamaguchi S; Kato S
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():79-84. PubMed ID: 25831728
    [No Abstract]   [Full Text] [Related]  

  • 59. Current research in side effects of high-dose chemotherapy.
    Wujcik D
    Semin Oncol Nurs; 1992 May; 8(2):102-12. PubMed ID: 1621001
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optic and otic side effects of molecular targeted therapies.
    O'Leary C
    Semin Oncol Nurs; 2014 Aug; 30(3):169-74. PubMed ID: 25085028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.